The effects of Herkinorin, the first μ-selective ligand from a salvinorin a-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 1, 2008, Pages 154-160

  Butelman, Eduardo R ^a   Rus, Szymon ^a   Simpson, Denise S ^b,c   Wolf, Angela ^c   Prisinzano, Thomas E ^b,c   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DRUG VEHICLE; HERKINORIN; KAPPA OPIATE RECEPTOR; LIGAND; LOPERAMIDE; MU OPIATE RECEPTOR; NALMEFENE; NALTREXONE; PROLACTIN; SALVINORIN A; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; RHESUS MONKEY; SEX DIFFERENCE;

ANIMALS; BIOLOGICAL MARKERS; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FURANS; LOPERAMIDE; MACACA MULATTA; MALE; NALTREXONE; PROLACTIN; PYRONES; RECEPTORS, OPIOID, MU;

EID: 52649127420     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.140079     Document Type: Article

References (28)

1. Aloi JA, Insel TR, Mueller EA, and Murphy DL (1984) Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Life Sci 34:1325-1331.
2. Bart G, Borg L, Schluger JH, Green M, Ho A, and Kreek MJ (2003) Suppressed prolactin response to dynorphin A(1-13) in methadone maintained versus control subjects. J Pharmacol Exp Ther 306:581-587.
3. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, and Kreek MJ (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappaopioid agonist activity? Neuropsychopharmacology 30:2254-2262.
4. Bowen CA, Negus SS, Kelly M, and Mello NK (2002) The effects of heroin on prolactin levels in male rhesus monkeys: use of cumulative dosing procedures. Psychoneuroendocrinology 27:319-336.
5. Brown NA and Bethea CL (1994) Cloning of decidual prolactin from rhesus macaque. Biol Reprod 50:543-552.
6. Butelman ER, Ball JW, and Kreek MJ (2002) Comparison of the discriminative and neuroendocrine effects of centrally-penetrating kappa-opioid agonists in rhesus monkeys. Psychopharmacology 164:115-120.
7. Butelman ER, Ball JW, and Kreek MJ (2004) Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic kappa-opioid agonists in rhesus monkeys. Psychoneuroendocrinology 29:307-326.
8. Butelman ER, Harris TJ, and Kreek M (1999) Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol 383:305-309.
9. Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, and Kreek MJ (2007) Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in non-human primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther 320:300-306.
10. Butelman ER, Reed B, Chait BT, Mandau M, Yuferov V, and Kreek MJ (2008) Limited effects of beta-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates. Psychoneuroendocrinology 33:292-304.
11. DeHaven-Hudkins DL, Burgos LC, Cassel JA, Daubert JD, DeHaven RN, Mansson E, Nagasaka H, Yu G, and Yaksh TL (1999) Loperamide (ADL-2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 289:494-502.
12. France CP and Gerak LR (1994) Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J Pharmacol Exp Ther 270:992-999.
13. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, and Bohn LM (2007) An opioid agonist that does not induce mu-opioid receptorarrestin interactions or receptor internalization. Mol Pharmacol 71:549-557.
14. Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, and Prisinzano TE (2005) Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem 48:4765-4771.
15. Hoehe M, Duka T, and Doenicke A (1988) Human studies on the mu opiate receptor agonist fentanyl: neuroendocrine and behavioral responses. Psychoneuroendocrinology 13:397-408.
16. Kreek MJ, Schluger J, Borg L, Gunduz M, and Ho A (1999) Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther 288:260-269.
17. Mello NK, Mendelson JH, and Kelly M (2000) Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys. Pharmacol Biochem Behav 66:275-283.
18. Merchenthaler I (1991) Neurons with access to the general circulation in the central nervous system of the rat: a retrograde tracing study with fluoro-gold. Neuroscience 44:655-662.
19. Nordström AL and Farde L (1998) Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 18:305-310.
20. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, and Ko MC (2008) Effects of mu-, kappa, and delta-opioid receptor agonists on the function of hypothalamic-pituitary adrenal axis in monkeys. Psychoneuroendocrinology 33:478-486.
21. Pecins-Thompson M, Brown NA, Kohama SG, and Bethea CL (1996) Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 16:7021-7029.
22. Prisinzano TE and Rothman RB (2008) Salvinorin A analogs as probes in opioid pharmacology. Chem Rev 108:1732-1743.
23. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, and Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99:11934-11939.
24. Ur E, Wright DM, Bouloux PM, and Grossman A (1997) The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol 120:781-784.
25. Valentino RJ, Katz JL, Medzihradsky F, and Woods JH (1983) Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 32:2887-2896.
26. Xu H, Partilla JS, Wang X, Rutherford JM, Tidgewell K, Prisinzano TE, Bohn LM, and Rothman RB (2007) A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse 61:166-175.
27. Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, and Osinski J (2002) Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 300:118-123.
28. Zheng SX, Bosch MA, and Rønnekleiv OK (2005) mu-Opioid receptor mRNA expression in identified hypothalamic neurons. J Comp Neurol 487:332-344.